Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (May 2022)
18 slides from Pyc Therapeutics's investor presentation, May 31, 2022
Slide 1: Corporate Presentation May 2022
For personal use only Corporate Life-changing science Presentation May 2022 1
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 3: Company Overview
Company Overview For personal use only PYC Therapeutics: • Designs and develops precision RNA therapies for patients with genetic diseases who currently have no treatment options available • Overcomes the major challenge in the precision medicine field (getting enough drug to the target) through its
Slide 4: PYC strives to change patient lives in markets worth >A$1 billion p.a. each
PYC strives to change patient lives in markets estimated to be worth > A$1 billion p.a. each For personal use only Estimated market opportunity Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 RP11 >A$1bn p.a.1 PYC-001 OPA1 ADOA >A$1.5bn p.a.2 PYC-002
Slide 5: PYC operates within a specific domain with a clear competitive advantage
PYC operates within a specific domain and with a clear competitive advantage For personal use only PYC’s probability of successful market entry is higher than the industry average and the Company benefits from the potential of a rapid path to market in the unmet needs it is addressing Orphan Estimat
Slide 6: PYC's RNA technology outperforms the industry standard by >100x in animal models
PYC’s RNA technology outperforms the ‘industry standard’ (‘naked’ RNA technology) by >100x in animal models For personal use only Drug administered to Drug trafficking Target engagement in mouse eye through retina target cells* • PYC’s RNA tech 100 versus % Target Engagement 80 • Industry standard t
Slide 7: Co-lead program for a blinding eye disease set to enter clinical trials in 1H 2023
PYC’s co-lead program for a blinding eye disease is set to enter clinical trials in 1H 2023 For personal use only Estimated market opportunity Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 RP11 >A$1bn p.a.1 PYC-001 OPA1 ADOA >A$1.5bn p.a.2 PYC-002 U
Slide 8: Retinitis Pigmentosa Type (RP11 Program)
Retinitis Pigmentosa Type 11 (RP11 Program) For personal use only Degenerative sight of RP11 patient • Onset from early childhood with sight deteriorating through adolescence and ultimately leading to blindness • Estimated 4k-8k addressable patients in the western world2 • No current treatment optio
Slide 9: Impact of next generation RP11 therapeutic visible in 'retina in a dish' models
The impact of PYC’s next generation RP11 therapeutic is clearly visible in patient-derived ‘retina in a dish’ models For personal use only Retinal pigmented epithelium (RPE) cells in a: 1. Healthy individual 2. Patient with RP11 3. Patient with RP11 after a single dose of PYC’s precision therapy A s
Slide 10: Initial focus on precision therapies for blinding eye diseases
PYC’s initial focus is on developing precision therapies for blinding eye diseases For personal use only PYC’s novel precision medicine modality is ideally suited to the treatment of blinding diseases of the retina Dimension of drug profile Evidence supporting Functional improvement in patient-deriv
Slide 11: PYC set to become a clinical-stage company with RP11 phase 1/2 in 1H 2023
PYC is set to become a clinical-stage company with the progression of the RP11 program into a combined phase 1/2 study in 1H 2023 For personal use only RP11 is well progressed through non-clinical testing and is on track to enter phase 1/2 clinical trials in human patients in 1H 2023 Achievements to
Slide 12: Precision therapy for a second blinding eye disease addresses a larger population
PYC’s precision therapy for a second blinding eye disease addresses a larger patient population than the RP11 program For personal use only Estimated market opportunity Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 RP11 >A$1bn p.a.1 PYC-001 OPA1 ADO
Slide 13: ADOA (OPA1 program)
ADOA (OPA1 program) For personal use only Autosomal dominant optic atrophy (ADOA) is a genetic disease causing progressive blindness ▪ The majority of ADOA cases are caused by mutations in the OPA1 gene leading to haploinsufficiency of the OPA1 protein1 ▪ Characteristics of OPA1 ADOA are: ‒ Severe,
Slide 14: Autosomal Dominant Optic Atrophy (ADOA Program)
Autosomal Dominant Optic Atrophy (ADOA Program) For personal use only 1 : 30,000 Prevalence of 1 in 30,000 people Estimated addressable Addressable market: in the western world4,5 population of 9k-16k patients Revenue >A$1.5bn p.a.* Primarily a pediatric disease with Orphan Drug pricing applicable C
Slide 15: PYC's team has the knowledge and experience required to deliver
PYC’s team has the knowledge and experience required to deliver For personal use only Board Alan Tribe Dr Michael Rosenblatt Jason Haddock Chairman Director Director Experience commercialising Senior Partner with Flagship Pioneering, Over 20 years’ experience in finance, operations Australian techno
Slide 16: The next months are transformational for PYC
The next 12 months are transformational for PYC For personal use only Timeline Q3 22 Q4 22 Q1 23 Q2 23 Domain GLP tox IND Phase 1/2 study commences in RP11 patients to RP11 studies submission establish safety of VP-001 with secondary efficacy read-outs Dose Range Finding Pharmacokinetic ADOA (rabbit
Slide 17: Addendum
Addendum For personal use only 1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: https://doi.org/10.1101/2020.11.02.20222232 2. Sullivan LS, Bowne SJ, Seaman CR, Blanton SH, Lewis RA, Heckenlively JR, et al. Genomic rearrangements of the PRPF31
Slide 18: Thank you
For personal use only Life-changing Thank you science 18